Withania somnifera extract reduces the invasiveness of MDA-MB-231 breast cancer and inhibits cytokines associated with metastasis

Abstract

Aim: The aim was to examine the anti-proliferative effect of a Withania somnifera (WS) root extract in cell cultures and nude mouse xenografts of breast cancer cell line MDA-MB-231.

Methods: WS root extract was used to treat tumor cells at concentrations up to 100 ug and for nude mouse experiments, the mice received daily WS at 300 mg/kg by oral gavage for 8 weeks.

Results: The WS extract reduced viability of MDA-MB-231 cells by 75% and 88% after exposure of the cells to 50 and 100 ug/mL, respectively, compared to vehicle-treated controls. WS extract caused a dose-dependent increase in the percentage of cells in the sub-G1 phase compared to untreated controls by 6% and 10% after exposure to 25 and 50 ug/mL WS extract, respectively. WS extract also inhibited proliferation of xenografted MDA-MB-231 cells. The WS extract caused reductions in xenograft size by 60% compared to the untreated control after 8 weeks of treatment. Six of ten mice in the control group showed tumor metastasis to the lung, whereas there was none in the mice treated with the WS extract. At the gene level, WS caused a 75% reduction in chemokine CCL2 expression (P < 0.05) in the xenografted tumors of the treated mice.

Conclusion: WS root extract inhibited proliferation of breast cancer cells in vitro and in vivo and significantly reduced expression of the cytokine, CCL2. These results warrant further studies to assess the underlying molecular mechanism of the anti-tumor activity of the WS extract in breast cancer.

Keywords

Withania somnifera extract / MDA-MB-231 / breast cancer / metastasis / animal model

References

[1] Cancer Facts and Figures. American Cancer Society; 204. Available from: http://www.cancer.org/research/cancerfactsstatistics/ cancerfactsfigures 204/ [Last accessed on 205 Mar 4].

[2] Triple Negative Breast Cancer. Available from: http:// www.nationalbreastcancer.org/triple-negative-breast-cancer [Last accessed on 015 Mar 14].

[3] Fisher B,Wickerham DL,Kavanah M,Vogel V,Dimitrov N,Daly M,Tan-Chiu E,Wolmark N.Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study..J Natl Cancer Inst1998;90:1371-88

[4] Cauley JA,Lippman ME,Krueger KA,Farrerons J,Mellstrom D,Stepan JJ,Morrow M,Silfen SL,Schmitt H,Jordan VC.Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation..Breast Cancer Res Treat2001;65:125-34

[5] Goss PE,Alés-Martínez JE,Chlebowski RT,McTiernan A,Johnson KC,Winquist E,Garber JE,Pujol P,Farmer P,Tu D,CTG MAP NCIC.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women..N Engl J Med2011;364:2381-91

[6] Kennecke H,Woods R,Voduc D,Nielsen TO.Metastatic behavior of breast cancer subtypes..J Clin Oncol2010;28:3271-7

[7] Mishra LC,Dagenais S.Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review..Altern Med Rev2000;5:334-46

[8] Winters M.Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology..Altern Med Rev2006;11:269-77

[9] Newman DJ.Natural products as sources of new drugs over the last 25 years..J Nat Prod2007;70:461-77

[10] Jayaprakasam B,Seeram NP.Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves..Life Sci2003;74:125-32

[11] Szarc vel Szic K,Ratman D,Beck IM,Heyninck K,Bracke M,Lardon F,Vanden Berghe W.Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells..PLoS One2014;9:e87850

[12] Senthilnathan P,Magesh V.Modulation of TCA cycle enzymes and electron transport chain systems in experimental lung cancer..Life Sci2006;78:1010-4

[13] Samuel T,Hyer M,Zapata JM.cIAP1 Localizes to the nuclear compartment and modulates the cell cycle..Cancer Res2005;65:210-8

[14] Li M,Snyder LA,Stewart TJ.A role for CCL2 in both tumor progression and immunosurveillance..Oncoimmunology2013;2:e25474

[15] Namdeo AG,Yadav KN,Mahadik KR,Kim HK,Verpoorte R.Metabolic characterization of Withania somnifera from different regions of India using NMR spectroscopy..Planta Med2011;77:1958-64

[16] Stan SD,Warin R.Withaferin A causes FOXO3a-and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo..Cancer Res2008;68:7661-9 PMCID:PMC2562581

[17] Subbaraju GV,Rao CV,Sridhar P,Nair MG.Ashwagandhanolide, a bioactive dimeric thiowithanolide isolated from the roots of Withania somnifera..J Nat Prod2006;69:1790-2

[18] Munagala R,Munjal C.Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells..Carcinogenesis2011;32:1697-705

[19] Yang Z,Xu S,Vertino PM,Marcus AI.Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition..PLoS One2013;8:e75069

[20] Qian BZ,Zhang H,Zhang J,Kaiser EA,Pollard JW.CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis..Nature2011;475:222-5 PMCID:PMC3208506

[21] Palacios-Arreola MI,Castro JI,Carrero JC.The role of chemokines in breast cancer pathology and its possible use as therapeutic targets..J Immunol Res2014;2014:849720 PMCID:PMC4139084

[22] Lee J,Marcus AI.Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors..Mol Carcinog2013;54:417-29 PMCID:PMC4039625

[23] Khazal KF,Hill DL.Effect of an extract of Withania somnifera root on estrogen receptor-positive mammary carcinomas..Anticancer Res2013;33:1519-23

[24] Khazal KF,Grubbs CJ.Effect of Withania somnifera root extract on spontaneous estrogen receptor-negative mammary cancer in MMTV/Neu mice..Anticancer Res2014;34:6327-32